Loading…
Based on limited metadata, the FDA issued a warning letter to Nalpropion Pharmaceuticals LLC, a drug manufacturer, on September 22, 2020. Without access to the full letter text or subject line, the specific nature of the violations cannot be determined from the available information. The warning falls under FDA drug product regulation, though the issuing office is not specified in the metadata provided. To understand the particular compliance concerns and required corrective actions, the complete warning letter would need to be reviewed.